On September 28, Hangzhou Derui Zhi Pharmaceutical Technology Co., Ltd. announced that it has reached an exclusive commercial cooperation covering mainland China, Hong Kong and Macau with Zhejiang Sansheng Mandy Pharmaceutical Co., Ltd., a subsidiary of Sansheng Pharmaceutical, and Wansheng Pharmaceutical on the AI-designed small molecule GLP-1 receptor agonist MDR-001 independently developed by Derui Zhi Pharmaceutical, covering mainland China, Hong Kong and Macau, with a potential total transaction amount of up to RMB 1.75 billion. According to the data, MDR-001 is currently carrying out a phase III key clinical study for adults who are obese or overweight in China.

On September 28, Hangzhou Derui Zhi Pharmaceutical Technology Co., Ltd. announced that it has reached an exclusive commercial cooperation covering mainland China, Hong Kong and Macau with Zhejiang Sansheng Mandy Pharmaceutical Co., Ltd., a subsidiary of Sansheng Pharmaceutical, and Wansheng Pharmaceutical on the AI-designed small molecule GLP-1 receptor agonist MDR-001 independently developed by Derui Zhi Pharmaceutical, covering mainland China, Hong Kong and Macau, with a potential total transaction amount of up to RMB 1.75 billion. According to the data, MDR-001 is currently carrying out a phase III key clinical study for adults who are obese or overweight in China.